

**Downregulation of oncogenic *RAS* and *c-Myc* expression in MOLT-4 leukaemia cells by a salicylaldehyde semicarbazone copper(II) complex**

**Yan-Yih Goh <sup>1\*</sup>, Yaw-Kai Yan <sup>1</sup>, Nguan Soon Tan <sup>2,3,4,5</sup>, Su-Ann Goh <sup>6</sup>, Shang Li <sup>6</sup>, You-Chuan Teoh <sup>1</sup>, and Peter P.F. Lee <sup>7</sup>**

<sup>1</sup>Natural Sciences & Science Education, National Institute of Education, Nanyang Technological University, 1 Nanyang Walk, Singapore 637616, Singapore, <sup>2</sup>School of Biological Sciences, Nanyang Technological University, 60 Nanyang Drive, Singapore 637551, <sup>3</sup>Lee Kong Chian School of Medicine, Nanyang Technological University, 50 Nanyang Avenue, Singapore 639798, Singapore, <sup>4</sup>Institute of Molecular and Cell Biology, 61 Biopolis Drive, Singapore 138673, Singapore, <sup>5</sup>KK Women's and Children's Hospital, 100 Bukit Timah Road, Singapore 229899, Singapore, <sup>6</sup>Duke-NUS Graduate Medical School, 8 College Road, Singapore 169857, Singapore, <sup>7</sup>Singapore Institute of Technology, 10 Dover Drive, Singapore 138683, Singapore

**\*Corresponding author**

**E -mail:** yanyih.goh@nie.edu.sg.

## Supplementary Information

### Methods


**Synthesis of 4-pentynyl nicotinate.** Nicotinic acid (0.948 g, 7.70 mmol) was added to a stirred solution of 4-pentyn-1-ol (0.647 g, 7.69 mmol) in freshly distilled dichloromethane (25 mL). *N, N'*-Dicyclohexylcarbodiimide (1.578 g, 7.65 mmol) and 4-(dimethylamino)pyridine (0.035 g, 0.29 mmol, 4 mol%) were then added to the mixture. The resultant suspension was stirred for 48 h in a stoppered round bottom flask at 25 °C. The reaction mixture (orange suspension) was then filtered and the yellow filtrate was evaporated under reduced pressure. The resultant residue was extracted using hexane (30 mL x 3) and the combined hexane extract was evaporated under reduced pressure. The white solid obtained was washed thoroughly with distilled water (30 mL x 3) and dried in a vacuum oven at 40°C for 4 h.

Yield: (314 mg, 1.66 mmol, 22%). Anal. Calcd for C<sub>11</sub>H<sub>11</sub>NO<sub>2</sub>: C, 69.8; H, 5.8; N, 7.4. Found: C, 69.9; H, 6.0; N, 7.5. IR (KBr, cm<sup>-1</sup>):  $\nu(\text{C}=\text{O})$  1712 vs,  $\nu(\text{C}\equiv\text{C}-\text{H})$  3253 vs,  $\nu(\text{C}\equiv\text{C})$  2109 vw. <sup>1</sup>H NMR [CDCl<sub>3</sub>, ppm]: 9.23 [1H, d, <sup>4</sup>J<sub>HH</sub> = 2 Hz, py H<sub>α</sub> (next to COO)], 8.78 (1H, dd, <sup>3</sup>J<sub>HH</sub> = 5 Hz, <sup>4</sup>J<sub>HH</sub> = 2 Hz, py H<sub>α</sub>), 8.30 (1H, dt, <sup>3</sup>J<sub>HH</sub> = 8 Hz, <sup>4</sup>J<sub>HH</sub> = 2 Hz, py H<sub>γ</sub>), 7.40 (1H, dd, <sup>3</sup>J<sub>HH</sub> = 8 Hz, <sup>4</sup>J<sub>HH</sub> = 5 Hz, py H<sub>β</sub>), 4.48 (2H, t, <sup>3</sup>J<sub>HH</sub> = 6 Hz, OCH<sub>2</sub>), 2.40 (2H, td, <sup>3</sup>J<sub>HH</sub> = 7 Hz, <sup>4</sup>J<sub>HH</sub> = 3 Hz) CH<sub>2</sub>C≡C, 2.03 (2H, quint, <sup>3</sup>J<sub>HH</sub> = 7 Hz CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>), 2.01 (1H, t, <sup>4</sup>J<sub>HH</sub> = 3 Hz C≡C-H).

**Preparation of (2,4-dihydroxybenzaldehyde dibenzyl semicarbazone) (4-pentynyl nicotinate) copper(II) nitrate (Complex 1\*).** Chlorido(2,4-dihydroxybenzaldehyde dibenzyl semicarbazone)copper(II) (38.4 mg, 0.081 mmol) was dissolved in 10 mL of methanol in a round bottom flask. One molar equivalent of silver nitrate (13.8 mg, 0.081 mmol) was added, and the mixture (shielded from light) was stirred vigorously for 2.5 h before it was filtered through Celite. The filtrate (dark green solution) was evaporated under reduced pressure to approximately 3 mL. 1 molar equivalent of 4-pentynyl nicotinate (15.3 mg, 0.081 mmol) was dissolved in 1 mL of methanol and added to the dark green solution. The resulting solution was stirred at r.t. for 2 h. Cold diethyl ether (40-

50 mL) was added, and the mixture was stored overnight at 4°C. The precipitate formed was isolated by filtration, washed with cold diethyl ether, and dried under vacuum at 40°C for at least 4 h.

Yield: (35.3 mg, 0.051 mmol, 64 %). Anal. Calcd for  $C_{33}H_{31}CuN_5O_8 \cdot 1\frac{1}{2} H_2O$ : C, 55.3; H, 4.75; N, 9.8. Found: C, 55.5; H, 4.9; N, 9.8. IR (KBr,  $cm^{-1}$ ):  $\nu(C=O)$  1724 vs,  $\nu(C\equiv C-H)$  3279 vs,  $\nu(C\equiv C)$  2115 vw.



**Figure S1.** Short term treatment of complex **1** does not induced significant changes in telomere length. Normal human fibroblast cells (IMR90) and cancer cells (MCF-7 and MOLT-4) are treated with complex **1** at different dosages for the indicated time. The genomic DNA was purified and the telomere length was measured using Genomic Southern analysis probed with telomere specific probe.

**Table S1.** Nucleotide sequences used for Fluorescence Intercalator Displacement (FID) assay.

Name of sequence	Nucleotide sequence
HTelo	5'- AGGGTTAGGGTTAGGGTTAGGG -3'
KRAS m(1:5:1)	5'- GGGAGGGAAGGAGGGAGGG -3'
KRAS m(1:9:1)	5'- GGGAGGGAAGGAGGGAGGGAGGG -3'
c-Kit21	5'- CGGGCGGGCGCGAGGGAGGGG -3'
c-Myc	5'- GGGAGGGTGGGGAGGGTGGG -3'
ds26	5'- CAATCGGATCGAATTCGATCCGATTG -3'
HIF1 $\alpha$	5'- CGGGGAGGGGAGAGGGGGCGGGA -3'
hTERT	5'- GGGGAGGGGCTGGGAGGGCCC -3'
VEGF22	5'- CGGGCGGGCCGGGGCGGGGT -3'

**Table S2.** Nucleotide sequences of primer sets used for quantitative real time PCR and qualitative *in-situ* Chem-ChIP.

Gene	Primer sequences	Amplicon size (bp)	PrimerBank ID <sup>1</sup>
<i>c-MYC</i>	5'- GGCTCCTGGCAAAGGTCA -3'	119	239582723c1
	5'- CTGCGTAGTTGTGCTGATGT -3'		
<i>c-KIT</i>	5'- CGTTCTGCTCCTACTGCTTCG -3'	117	148005048c1
	5'- CCCACGCGGACTATTAAGTCT -3'		
<i>KRAS</i>	5'- TGTGTCTCATATCAGGTTGACGA -3'	170	209529676c1
	5'- CAAGAGTCGAGTGTGGTCTCA -3'		
hTERT	5'- AAATGCGGCCCTGTTTCT -3'	76	301129199c1
	5'- CAGTGCCTTGAGGAGCA -3'		
$\beta$ -tubulin	5'- TGGACTCTGTTGCTCAGGT -3'	155	34222261c1
	5'- TGCCTCCTTCCGTACCACAT -3'		
<i>GAPDH</i>	5'- GGAGCGAGATCCCTCCAAAAT -3'	197	378404907c1
	5'- GGCTGTTGTCATACTTCTCATGG -3'		
$\beta$ -actin	5'- CATGTACGTTGCTATCCAGGC -3'	250	4501885a1
	5'- CTCCTTAATGTCACGCACGAT -3'		
KRAS <sub>prom</sub> <sup>2</sup>	5'- TTCTCCCCGCCGGCGCTCGC -3'	95	-
	5'- CTCGATTCTTCTTCAGACGG -3'		
c-MYC <sub>prom</sub> <sup>3</sup>	5'- AGTGCTCGGCTGCCCGGCTGA -3'	106	-
	5'- CTTTCCCCCAGCCCTCTGC -3'		
HTelo (TRAP assay)	5'- AATCCGTCGAGCAGAGTT -3'	50-300	-
	5'- GCGCGGCTTACCCTTACCCTTACCCTAACC -3'		
Negative (human chromosome 3 <sup>4</sup> )	5'- TAGGCTGGAGGTCGTGGTTA -3'	293	-
	5'- CGGCGCTTTCGGATTA ACT -3'		

- 1 Wang, X., Spandidos, A., Wang, H. & Seed, B. PrimerBank: a PCR primer database for quantitative gene expression analysis, 2012 update. *Nucleic Acids Res* **40**, D1144-1149, doi:10.1093/nar/gkr1013 (2012).
- 2 Cogoi, S. & Xodo, L. E. G-quadruplex formation within the promoter of the KRAS proto-oncogene and its effect on transcription. *Nucleic Acids Res* **34**, 2536-2549, doi:10.1093/nar/gkl286 (2006).
- 3 Siebenlist, U., Hennighausen, L., Battey, J. & Leder, P. Chromatin structure and protein binding in the putative regulatory region of the c-myc gene in Burkitt lymphoma. *Cell* **37**, 381-391 (1984).
- 4 Thakur, R. K. *et al.* Metastases suppressor NM23-H2 interaction with G-quadruplex DNA within c-MYC promoter nuclease hypersensitive element induces c-MYC expression. *Nucleic Acids Res* **37**, 172-183, doi:10.1093/nar/gkn919 (2009).